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Abstract
Background: Recurrent bacterial infections of the respiratory tract are one of the major clinical features of the
primary ciliary dyskinesia (PCD), a rare genetic disease due to malfunctioning of motile cilia. Chronic infections and
persistent inflammation of the respiratory system result in progressive lung disease.
Aim of the study was to highlight the main factors associated with clinical, functional and anatomical deterioration
in PCD patients.
Methods: We retrospectively analyzed data from 58 patients with PCD, 37 adults and 21 children. The
demographic and clinical data, forced expiratory volume at 1 s (FEV1) and forced vital capacity (FVC), sputum
microbiology and imaging results (chest CT scores-modified Bhalla) were recorded. Patients were stratified
according to the number of exacerbations (< 2/year vs ≥ 2/year) and chronic Pseudomonas aeruginosa (PA)
colonization. The possible correlations between lung function and chest CT scores were assessed; we also evaluated
the correlation between these parameters and the severity scores for bronchiectasis (BSI, FACED and e-FACED).
Results: Chest CT scores showed a significant correlation with FEV1 (p = 0.0002), age (p < 0.0001), BMI (p = 0.0002)
and number of lung lobes involved (p < 0.0001). PA colonization had an overall prevalence of 32.6%: no significant
difference in FEV1 between PA colonized and non-colonized patients was found (p = 0.70), while chest CT score was
significantly worse in chronic PA colonized patients (p = 0.009). Patients with a high number of exacerbation (≥ 2/
year) were older (p = 0.01), had lower FEV1 (p = 0.03), greater number of lobes involved (p < 0.001) and worse CT
score than patients with low number of exacerbations (p = 0.001); they also had higher prevalence of PA chronic
bronchial infection (33.3% versus 13.6%, p = 0.10). Multivariable linear regression analyses adjusted for gender, age
and BMI showed positive associations between PA colonization and number of exacerbations with severity of
disease (number of lobes involved, CT score, BSI, FACED, and e-FACED).
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Conclusions: In our PCD population the number of exacerbations (≥ 2/year) and PA colonization were the two
most relevant factors associated with severity of disease.
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Background
Primary ciliary dyskinesia (PCD, MIM #244400; http://
www.ncbi.nlm.nih.gov/Omim/) is a rare, genetic and
clinically heterogeneous disease, characterized by dis-
order of motile cilia in structure or function, resulting in
chronic upper and lower respiratory tract disease, left-
right laterality defect in approximately 50% of cases and
infertility.
The disease has been described in 1933 by Kartagener
as a triad of chronic sinusitis, bronchiectasis and situs
viscerum inversus [1]. Afzelius in 1976 reported that
these patients have immotile cilia and defective ciliary
ultrastructure [2].
A prevalence of approximately 1 in 15,000 newborns
has been estimated [3]. Age at presentation ranges from
birth to adulthood. In the newborns, the clinical presen-
tation of PCD is characterized by occurrence of respira-
tory distress in > 80% of cases [4], daily nasal congestion
and wet cough starting soon after birth; recurrent or
chronic middle ear and sinus disease develop early and
most PCD patients demonstrate severe pansinusitis on
computed tomography (CT) scan [5].
Recurrent pneumonia or bronchitis are very common
in PCD, and in children with recurrent respiratory infec-
tions the prevalence of PCD can be as high as 5% [6].
Bronchiectasis may be present already in children with
PCD, affect primarily the middle lobe, lingula and lower
lobes and are age-dependent [4, 5]. As the airway disease
does progress with age, consolidative areas, atelectasis and
bronchiectasis become constant findings in adults [7].
There is no a pathognomonic test for the diagnosis of
PCD. Therefore, a panel of tests, including nasal nitric
oxide (nNO), transmission electron microscopy (TEM),
evaluation of ciliary motility and genetic analysis, is often
required for a final diagnosis of PCD [8]. The clinical
features for patients who must be referred to diagnostic
tests for PCD are reported by European Respiratory So-
ciety guidelines in 2017 [9].
Respiratory infections are major determinants of mor-
bidity and mortality in patients with PCD, as they are
correlated to a poor quality of life [10] and to functional
decline [11]. Haemophilus influentiae and Streptococcus
pneumoniae appear to be the most common pathogens
isolated from patients with PCD during early childhood
[4, 12]. In adult patients sputum cultures during exacer-
bations yield pathogens such as Haemophilus influentiae,
Staphylococcus aureus, Streptococcus pneumoniae and
Pseudomonas aeruginosa (PA) [13].
Exacerbations in children and adults with PCD, de-
fined as an acute increase in respiratory symptoms [14],
characterize the natural history of the disease.
During exacerbation, PCD patients clinically present a
significant reduction in FEV1 and approximately 25% of
children with PCD fails to recover to baseline lung func-
tion after treatment of a pulmonary exacerbation with
intravenous antibiotics [15].
Although the severity of exacerbations has been corre-
lated to the decline of lung function in adult patients
with non-CF bronchiectasis [16], the effect of the num-
ber of exacerbations on the disease severity in patients
with PCD has not yet investigated.
PA is an important pathogen in PCD, with an overall
reported prevalence ranging between 27 and 35% [17].
In PCD the presence of PA colonization appears to in-
crease with age [12, 17, 18].
Although it is well known that chronic infection with
PA is associated with a decrease in lung function and an
increased risk of death in patients with cystic fibrosis
(CF) [19, 20], it is unclear to what extent PA
colonization also contributes to the decline of lung func-
tion in PCD patients.
In this study we primarily aimed to evaluate if the
number of exacerbations and PA colonization are associ-
ated with lung function decline and structural damage in
a group of PCD patients.
Methods
We retrospectively analysed data of 58 (21 children and
37 adults) clinical cases of PCD who have been diag-
nosed and followed up during the last 10 years at Center
for Rare Diseases, Unit of Respiratory Diseases of the
Policlinico Hospital, Milan. The Ethical Committee of
the Hospital approved protocol and a written informed
consent was obtained from the adult patients or parents
of children.
Patients with a history suggestive for PCD were con-
sidered “PCD case” in presence of hallmark ciliary elec-
tron microscopy defect [21, 22], and/or in case of
identification of non-ambiguous biallelic mutations in
known PCD-associated genes (patients “PCD positive”)
[7, 23]. Patients with a clinical suspicious of PCD who
do not fulfill at least one of the above mentioned criteria
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to make a certain diagnosis (e.g patients with normal cilia
ultrastructure at TEM and/or patients with no evidence of
unambiguous biallelic mutations in known PCD-
associated genes) were considered as “highly likely PCD”
by the result of the combination of other diagnostic test,
e.g. repeated low levels of nasal nitric oxide, and abnormal
ciliary motility, according to ERS Guidelines [23].
Nasal nitric oxide (nNO) assessments were achieved in
patients over 5 years from a chemiluminescence analyzer
(CDL Ecomedics, Dürnten, Switzerland) using a single-
breath online method at a constant flow rate of 50 mL/s.
Values of nNO < 77 nL/min were considered as cut-off
[24, 25].
Ciliary motility was studied on fresh respiratory epi-
thelium (within 15 min) at 25 °C, under an Olympus
BH-2 optical microscope equipped with Nomarsky inter-
ferential contrast and a heated stage; samples were ob-
tained by cytology brushing on the nasal inferior
turbinate. Ciliary beat frequency (CBF) (normal range:
11–20 Hz) [26] and ciliary beat pattern (CBP) were de-
termined as previously published [27].
We also obtained samples of nasal mucosa by brushing
for processing and observation at transmission electron
microscopy (TEM). Samples of respiratory epithelium ob-
tained by nasal brushing were fixed in 2.5% cacodylate-
buffered glutaraldehyde, post-fixed in buffered 1% osmium
tetroxide, dehydrated, embedded in resin; ultrathin sec-
tions were double-stained with uranyl-acetate and lead cit-
rate and examined at 100 kV with a Philips 208S
transmission electron microscope. At least 50 cross sec-
tions of cilia from different cells were observed in each
specimen. Electron micrographs were taken at a magnifi-
cation of X 110,000 to study the internal axonemal struc-
ture. The ultrastructural phenotype was defined as the
main ultrastructural defect and the percentage of abnor-
mal cilia among the total number of cilia was analysed,
considering nonspecific defect when present up to 10% of
cilia [21]. We considered hallmark diagnostic defects for
PCD as reported by International Consensus guideline
(BEAT PCD TEM Criteria) [28]; inner dynein arm (IDA)
defects were not considered diagnostic except when ap-
parent on repeated biopsies [22].
Genetic analysis was performed on genomic DNA ex-
tracted from peripheral blood according to standard pro-
tocols [29] and PCR amplified to study mutations in
dynein genes using a DNA isolation kit (Roche, Milano,
Italy); Next Generation Sequencing (NGS) was applied
to study mutations on PCD-known genes (ACVR2B,
CFC1, CRELD1, FOXH1, GJA1, LEFTY2, NKX2–5,
NODAL, ZIC3, DNAH5, DNAI1, DNAI2, CCDC39,
CCDC40, DNAH11, KTU/DNAAF2, LRRC50/DNAAF1,
TXNDC3/NME8, DNAL1, INVS/HPHP2, DNAAF3,
RSPH4A, RSPH9, OFD1, RGPR, CCDC103, HEATR2,
HYDIN, LRRC6, DYX1C1) [23].
General clinical data
Clinical anamnestic data were collected with special
focus on the presence of upper and lower recurrent re-
spiratory infections and on the number and severity of
exacerbations; they were recorded during the routine
visits of follow-up, usually occurring every three-four
months.
In children older than 5 years of age, spirometry was
performed according to the American Thoracic Society/
European Thoracic Society (ATS/ERS guidelines) [30].
Results were expressed as a percentage of the predicted
value for height and age; volumes and flows were con-
sidered as normal when > 80% of the expected value.
Usually, each patient performed at least one spirometry
per year; for the purpose of this assessment, the most re-
cent examination was considered.
Lower airways involvement
Diagnosis of bronchiectasis was based on criteria re-
ported by Naidich et al. for chest CT scan [31]. For pa-
tients who had more than one chest CT scan, the more
recent was taken into account to establish the severity of
lung disease; anyway, no more than 6 months elapsed
between chest CT scan and spirometry performing. The
extent of bronchiectasis, severity of bronchial dilatation,
bronchial wall thickness, presence of mucus plugging in
large and small airways and decrease in parenchymal at-
tenuation were scored for each lobe according to the
modified Bhalla high-resolution computed tomography
scoring system (mBhalla) [32]. Lingula was considered as
separate lobe. If lobectomy had been performed a sever-
ity score of 3 was assigned to the missing lobe by arbi-
trary definition and distribution was presumed diffuse.
The mean score for all lobes for each abnormality was
calculated and lobar predominance was assessed. The
CT scores ranged between 0 and 48.
In addition to mBhalla scoring system, BSI, FACED and
e-FACED scores were also calculated, as multidimensional
scoring systems created and validated to classify the sever-
ity of bronchiectasis [33–35]. BSI identifies patients at risk
of future mortality, hospital admissions and exacerbations;
FACED classifies the severity of bronchiectasis according
to 5-years prognosis; e-FACED detects patients with more
frequent exacerbations. Classification of severity was
stratified into mild, moderate and severe according to the
original Authors designations.
Microbiological data
All available sputum cultures were analyzed: each patient
had at least three sputum bacteriology per year; included
patients had microbiological data for at least 1 year.
Chronic bronchial infection was defined as the isolation
of the same pathogen in sputum culture on two or more
occasions, at least 3 months apart in a 1-year period
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[36]. Similarly, regarding PA colonization, we classified pa-
tients as non-colonized if they had never been cultured or
cultured only once with this pathogen, and as colonized
patients if they showed at least two positive sputum cul-
tures for PA in 1 year (3months apart) [18, 36].
Number of exacerbations
We considered the definition of exacerbation in PCD as
indicated by expert consensus (14). As the median of ex-
acerbations was 2 per year prior to the analysis in our
patients, we classified patients in two groups: Low-
EXAC: < 2/year and High-EXAC ≥2/year.
Statistical analysis
Mann-Whitney test and chi-square test were used to
compare quantitative and categorical variables, respect-
ively. We calculated Spearman’s rho correlation coeffi-
cient to evaluate the association between age, BMI, and
indexes of anatomical and functional lung damage. We
examined the relationship (slopes and 95% confidence
intervals (CI)) between the dependent variables FEV1,
FVC, number of lung lobes, chest CT score, BSI, FACED
and e-FACED and the independent variables gender
(males versus females), age (in 10 years), BMI (Kg/m2),
PA colonization (yes/no) and exacerbation frequency (≥2
versus < 2) using univariate and multivariable linear re-
gression models. Statistical analyses were performed
with Stata 15 (StataCorp. 2017).
Results
The study included 58 patients admitted between 2007
and 2017: 33 males and 25 females; 37 adults, mean age
39.4 years (range: 19–70), 21 children, mean age 11.1
years (range: 2–17).
A “positive PCD diagnosis” was met by 51 out of the
58 patients; a “highly likely PCD diagnosis” was met by 7
patients who had clinical history suggestive for PCD, low
nasal nitric oxide in more occasions, and repeated ab-
normal ciliary motility; in these subjects genetic tests re-
sulted negative, but all showed situs inversus and five
had bronchiectasis at chest CT.
Demographic and clinical characteristics of all patients
are summarized in Table 1.
Table 2 shows the results of diagnostic tests for PCD.
The diagnosis of PCD was made at a mean age of 26.5
years in adults and 4.3 years in pediatric patients.
Body mass index (BMI) was significantly correlated
with the age of subjects (n. 58, rho = 0.71, p < 0.0001).
Chest CT scan were available for 56 patients: the main
findings in our patients with PCD included bronchiec-
tasis, atelectasis, mucus plugging, peribronchial thicken-
ing and air trapping.
CT scan showed bronchiectasis in 32/37 (86.5%) of
adults and in 6 (28.6%) of children, most often
cylindrical bronchiectasis. The mean number of lobes in-
volved: 1.8 ± 1.5, with a significant correlation with age
(n. 56, rho = 0.62, p < 0.0001). The lung bases were more
frequently involved than the upper lobes; the middle
lobe and the lingular segment showed the most severe
lesions.
Chest CT score (mBhalla) correlated with age (n. 56,
rho = 0.63, p < 0.0001), BMI (n. 56, rho = 0.48, p =
0.0002), FEV1 (n. 45, rho = − 0.53, p = 0.0002) and num-
ber of lobes involved (n. 56, rho = 0.96, p < 0.0001).
No correlation was found between mBhalla score and
age of diagnosis or between FEV1 and age of diagnosis.
As showed in Table 3, we found moderate to strong
positive correlations between indexes of structural pul-
monary impairment and substantial negative correlations
between functional and anatomical indexes: in particular,
lung structural damage measured by mBhalla score and
the number of lung lobes involved are related to de-
creased respiratory function, considering FEV1 and FVC
deviation from predictive value.
Table 1 Characteristics of patients reported as number and
percentage or mean ± SD
Children Adults
Number of patients (%) 21 (36.2) 37 (63.8)
PCD positive 18 (85.7) 33 (89.2)
PCD highly likely 3 (14.3) 4 (10.8)
Males (%) 7 (33.3) 19 (51.3)
Age in years (mean ± SD) 11.1 ± 4.6 39.4 ± 14.4
Age at diagnosis (mean ± SD) 4.3 ± 4.2 26.5 ± 16.2
Situs inversus (%) 14 (66.6) 22 (59.4)
Situs solitus (%) 6 (28.6) 15 (40.5)
Situs ambiguous (%) 1 (4.8) 0 (0.0)
Lobectomy (%) 1 (4.8) 5 (13.5)
Percentage of predicted value
FEV1 (mean ± SD) 93.3 ± 18.7 72.5 ± 23.4
FVC (mean ± SD) 103.5 ± 15.6 85.2 ± 21.7
Exacerbations (mean ± SD) 1.6 ± 1.0 2.3 ± 1.1
Exacerbations ≥ 2/year (%) 10 (47.6) 26 (70.3)
Colonization by:
Pseudomonas aeruginosa 3 (14.3) 12 (32.4)
Other pathogens 9 (42.8) 9 (24.3)
Chest CT score (mBhalla) 2.6 ± 6.2 16.2 ± 9.5
Bronchiectasis (%) 6 (28.6) 32 (86.5)
Lobes (mean ± SD) 0.6 ± 1 2.5 ± 1.3
Severity of bronchiectasis
BSI 2.5 ± 3.1 5.1 ± 4.3
FACED 0.4 ± 0.8 1.2 ± 1.2
eFACED 0.8 ± 1.4 2.1 ± 2.0
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Concerning the respiratory function, FEV1 was signifi-
cantly correlated with age (n. 46, rho = − 0.38, p = 0.01).
Instead, no relationship was observed between respira-
tory function parameters and ultrastructural phenotype
and/or genotype.
Table 4 shows the distribution of subjects stratified ac-
cording to the multidimensional severity scores for
bronchiectasis: BSI, FACED, e-FACED; according to
these scores, most patients were classified as mild or
moderate in severity, although, especially BSI, found
some subjects as severe.
Chronic bacterial colonization was present in 12/21
(57.1%) children and in 21/37 (56.8%) adults subjects.
Predominant pathogens were Haemophilus influentiae
(36.9%), Staphylococcus aureus (15.2%), Streptococcus
pneumoniae (13.0%), Escherichia coli (8.7%) and Morax-
ella catharralis (6.5%). No patients had non-tuberculous
mycobacteria. In 10 cases, no pathogens were cultured
in sputum. Microbiological data were missing or incom-
plete in 12 subjects. Fifteen subjects, 12 adults and 3
children, corresponding to 32.4 and 14.3% respectively,
had a chronic colonization by Pseudomonas aeruginosa.
The overall prevalence of PA colonization was 32.6%.
Patients with chronic PA colonization were older than
noncolonized patients: 34.4 ± 16.1 years versus 27.4 ±
18.6 years (p = 0.10). PA colonized patients also show
worse chest CT score (p = 0.009), while we did not ob-
served differences in FEV1 values (p = 0.70) between col-
onized and non-colonized patients, probably due to the
limited number of PA colonized patients in our study.
Patients with a high number of exacerbations (≥ 2/
year) were older (p = 0.01) and had lower FEV1 (p = 0.03)
compared to patients with few exacerbations (< 2/year).
The number of lung lobes involved (p < 0.001) and worse
mBhalla scores (p = 0.001) were also positively associated
with the number of exacerbations. Finally, a high num-
ber of exacerbations (≥ 2/year) patients showed a trend
of higher prevalence of PA chronic bronchial infection
than low exacerbation (< 2/year) patients (33.3% versus
13.6%, p = 0.10) (Table 5).
Table 2 Results of the diagnostic testing
All (%) Children (%) Adults (%)
nNO (nL/min) 45 (100) 13 (100) 32 (100)
Low (< 77) 34 (75.6) 11 (84.6) 23 (31.9)
Normal (≥ 77) 11 (24.4) 2 (15.4) 9 (28.1)
Ciliary motility 50 (100.0) 17 (100.0) 33 (100.0)
Complete immotility 11 (22.0) 1 (5.9) 10 (30.3)
Reduced CBF (< 5 Hz) 22 (44.0) 9 (52.9) 13 (39.4)
Reduced CBF (5–10 Hz) 4 (8.0) 1 (5.9) 3 (9.1)
Within normal range (> 10 Hz) 2 (4.0) 1 (5.9) 1 (3.0)
Absence of cilia 11 (22.0) 5 (29.4) 6 (18.2)
Ciliary beat pattern 50 (100.0) 17 (100.0) 33 (100.0)
Complete immotility 11 (22.0) 1 (5.9) 10 (30.3)
Minimal residual movement 12 (24) 5 (29.4) 7 (21.2)
Extremely stiff 8 (16) 2 (11.8) 6 (18.2)
Reduced proximal bending 6 (12) 3 (17.6) 3 (9.1)
Circular beating cilia 2 (4) 1 (5.9) 1 (3)
Absence of cilia 11 (22.0) 5 (29.4) 6 (18.2)
TEM ultrastructure 54 (100.0) 19 (100.0) 35 (100.0)
Only ODA absence 12 (22.2) 2 (10.5) 10 (28.6)
ODA + IDA absence 10 (18.5) 1 (5.3) 9 (25.7)
ODA + IDA absence + CC defect 2 (3.7) 1 (5.3) 1 (2.9)
IDA absence +MTD 12 (22.2) 9 (47.4) 3 (8.6)
CC defect 6 (11.1) 2 (10.5) 4 (11.4)
Only IDA absence 3 (5.6) 0 (0) 3 (8.6)
Normal 9 (16.7) 4 (21) 5 (14.2)
Genetic analysis 42 (100.0) 15 (100.0) 27 (100.0)
No mutations 16 (38.1) 6 (40.0) 10 (37.0)
DNAH5 Mutations 15 (35.7) 5 (33.3) 10 (37.0)
DNAH11 Mutations 6 (14.3) 2 (13.3) 4 (14.9)
DNAI1 Mutations 3 (7.1) 1 (6.7) 2 (7.4)
Other mutations 2 (4.8) 1 (6.7) 1 (3.7)
ODA = Outer Dynein Arm; IDA = Inner Dynein Arm; CC = Central Complex; MTD
= Microtubular disorganization
Table 3 Correlation (Spearman’s rho coefficients) between indexes of anatomical and functional lung damage
Number of lung lobes mBhalla BSI FACED e-FACED FEV1
mBhalla 0.94
BSI 0.64 0.62
FACED 0.70 0.64 0.84
e-FACED 0.74 0.69 0.92 0.92
FEV1 - 0.50 - 0.55 - 0.48 - 0.51
- 0.52
FVC - 0.40 - 0.45 - 0.46 - 0.37
- 0.48
0.77
n = 43; All p-values < 0.02
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In univariate analyses age, BMI, PA colonization and a
high number of exacerbations (≥2/year) were associated
with number of lung lobes involved, chest CT score and
multidimensional scoring systems (BSI, FACED and e-
FACED) (Table 6, upper part). In a multivariable ana-
lysis, after adjusting for age, sex and BMI, PA
colonization was positively associated with BSI, FACED,
and e-FACED, while a high number of exacerbations
was positively associated with number of lung lobes in-
volved, chest CT score, BSI, and e-FACED (Table 6,
lower part).
Discussion
This single centre, retrospective, cross-sectional study
performed in both adults and children PCD patients,
demonstrated a correlation between functional respira-
tory impairment, expressed by FEV1 and FVC deviation
from predicted values, and lung structural damage,
expressed by the number of lung lobes involved and
higher chest CT scores. Our results are in agreement
with those reported by other Authors [37–39]. In
addition, our study aimed to assess how much two rele-
vant factors as the exacerbations number and chronic
PA colonization are related to functional and structural
decline in PCD patients.
The exacerbations in PCD, defined as an acute in-
crease in respiratory symptoms [14], are predictors of se-
verity of disease and poor quality of life [10] and
negatively impact on lung function, as bacterial infec-
tions are associated with morbidity and mortality in
these patients [13]. It was reported that about 25% of
children with PCD fail to recover to baseline lung func-
tion within 3months following a pulmonary exacerba-
tion treated with intravenous antibiotics and may never
regain pre-exacerbation spirometry [15]. In PCD pa-
tients, during exacerbation, Ratjien et al. [40] observed
that FEV1 drops from its previous baseline around a me-
dian change of 22%; they also reported that during pul-
monary exacerbations in PCD patients, sputum analysis
demonstrated neutrophilic airway inflammation, high
interleukin IL-8 sputum concentrations and increased
neutrophil elastase activity that is associated with lung
decline over time, while neutrophil elastase decreased
after antibiotic therapy.
In non-FC bronchiectasis patients the number of exac-
erbations is one of the major markers of disease activity
and it is strictly related to prognosis in the short and
long term [16]: the number and severity of exacerbations
and the presence of PA chronic colonization are two fac-
tors both related with decline in lung function. Chalmers
et al. [41] reported that in non-FC bronchiectasis pa-
tients, severe exacerbations were associated with more
extensive bronchiectasis in terms of number of lobes in-
volved or the presence of cystic bronchiectasis: for this
reason, the identification of subjects at highest risk of
functional decline is extremely important to avoid lung
deterioration.
For the first time, our evaluation in PCD patients shows
that the number of exacerbations (≥ 2/year) correlates
with the severity of disease, in terms of structural damage
and lung function severity of impairment: our data suggest
that PCD patients with more than 2 exacerbations per
year require a more careful surveillance to reduce and pre-
vent a worsening of their respiratory conditions.
In the present study, patients were examined mostly in
the clinical stability phase, so the data on the number
Table 4 Severity of PCD patients according to multidimensional
indexes for bronchiectasis
Children (n) Adults (n)
Patients 16 34
BSI (%)
Mild 0–4 12 (75.0) 21 (61.8)
Moderate 5–8 3 (18.8) 5 (14.7)
Severe ≥ 9 1 (6.2) 8 (23.5)
FACED (%)
Mild 0–2 15 (93.8) 31 (91.2)
Moderate 3–4 1 (6.2) 3 (8.8)
Severe 5–7 – –
eFACED (%)
Mild 0–2 14 (87.6) 20 (58.9)
Moderate 3–4 1 (6.2) 11 (32.3)
Severe 5–7 1 (6.2) 3 (8.8)
Table 5 . Distribution of selected parameters (mean ± SD) according to the two groups of patients stratified by the number of
exacerbations
High number of exacerbations (≥ 2/year) Low number of exacerbations (< 2/year) p
Age (years) 33.9 ± 18.4 21.4 ± 14.9 0.01
BMI (Kg/m2) 21.6 ± 4.6 18.6 ± 4.2 0.02
FEV1 (% of predicted value) 73.7 ± 22.7 89.1 ± 24.2 0.03
Number of lung lobes 2.3 ± 1.4 0.9 ± 1.2 < 0.001
Chest CT score (mBhalla) (0–48) 14.8 ± 10.8 5.2 ± 7.1 0.001
PA colonization (%) 33.3 13.6 0.10
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and severity of exacerbations were predominantly anam-
nestic; overall, exacerbations were reported as mild or
moderate, and only in some case hospitalization was ne-
cessary. On the other hand, the study was not focused
on the severity of exacerbations but rather on the im-
portance of the number of exacerbations themselves.
About the results of microbiology of sputum, they re-
sulted in agreement with the results of other studies that
reported Haemophilus influentiae and Pseudomonas aeru-
ginosa as the most common pathogens in PCD [12, 18].
We found a prevalence of chronic PA colonization of
14.2% in children and 32.4% in adults; our data are simi-
lar to those reported by Wijers et al. who found that
prevalence of PA colonization increases with the age, es-
pecially after age 30 in PCD, as in CF patients [13].
Considering both pediatric and adult PCD patients,
Cohen Cymberknoh [18] also reported an overall preva-
lence of PA colonization of about 27%; those colonized
with PA were older and diagnosed at a later age. Simi-
larly, we observed that chronic PA lung colonization in
PCD was associated with older age.
Identification of PA has been considered a key deter-
minant of bronchiectasis severity in three recently devel-
oped severity scoring systems: the Bronchiectasis
Severity Index (BSI), the FACED and e-FACED score
that are multidimensional scores combining clinical,
microbiological and radiological variables to evaluate the
prognosis and severity of bronchiectasis [33–35].
In our study, PA colonized patients show worse chest
CT score, as well as patients with number of exhacerba-
tions > 2/year; FEV1 did not differ between colonized
and non-colonized patients, but this result may be at-
tributed to the small number of patients with PA
colonization in this study. However, although we have
not carried out a longitudinal study, the rate of decline
in FEV1 derived from age classes between the colonized
and the noncolonized groups was similar to those re-
ported previously by Cohen-Cymberknoh et al. [18] and
by Davis et al. [42].
In the study of Finch [43] the chronic PA colonization
has been demonstrated to have a negative prognostic
impact on non-FC bronchiectasis: adult patients with
bronchiectasis colonized by PA had a threefold higher
risk of mortality and a sevenfold greater risk of hospital
admission.
Our results address the importance of early identifying
and treating PA colonization to avoid lung structural
damage in PCD patients. We applied the most frequent
definition used in non-cystic fibrosis bronchiectasis stud-
ies for bacterial colonization that is “two or more isolates
of the same microorganism at least three months apart
in one year” [36, 43]. It is possible that microbiological
studies on PCD patients may apply more stringent cri-
teria to stratify subjects.
Conclusions
The limitations of our study are due to its retrospective
nature which precludes the possibility of proving a clear
causal relationship between the number of chest exacer-
bations and PA colonization with the lung structure and
function decline, even if an association between these
factors can be hypothesized. Our results would require
confirmation in larger studies, possibly using a prospect-
ive cohort design. For the future, a larger international
studies should be carried out to better identify predictors
of bronchiectasis development and lung function wors-
ening in patients affected by PCD. However, our study
performed as single centre included a relatively high
number of patients both children and adults patients af-
fected by PCD, a rare disease.
The use of different scores of lung structural damage,
especially FACED and e-FACED, are easy to apply in
clinical practice, since they require knowledge of a few
clinical variables related to patients and demonstrate to
be useful in PCD subjects for the stratification of the dis-
ease severity, rather than performing the more complex
evaluation of the extent of lesions at chest CT, mainly
used for research purposes.
Our data also underline the possibility to stratify PCD
patients according to the aforementioned risk factors (≥
2 exacerbations/year and PA colonization) and to inten-
sify treatment of the airway infections at the first sign of
worsening respiratory symptoms to prevent lung func-
tion and structure deterioration.
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